Drugs / Sovleplenib
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07348133 | Dec 2025 → Jan 2026 | — | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT06291415 | Apr 2024 → Apr 2026 | autoimmune thrombocytopenia, platelet disorder, undefined, primary thrombocytopenia, skin disorder +1 | Hutchmed | Withdrawn | No outcome recorded |
| Phase 1 | NCT05781906 | Feb → Jun 2023 | autoimmune thrombocytopenia | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05720767 | Nov 2022 → Feb 2023 | lymphoma | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05571787 | Jul → Sep 2022 | lymphoma | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT03779113 | Sep 2019 → Feb 2025 | non-Hodgkin lymphoma | Hutchmed | Terminated | No outcome recorded |
| Phase 1 | NCT03483948 | Oct 2018 → Sep 2019 | acute myeloid leukemia | Hutchison Medipharma Limited | Terminated | No outcome recorded |
| Phase 1 | NCT02857998 | Dec 2016 → Jun 2021 | neoplasm of mature B-cells | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT02503033 | Nov 2015 → Dec 2020 | hematopoietic and lymphoid system neoplasm | Hutchison Medipharma Limited | Unknown | No outcome recorded |
| Phase 1 | NCT02105129 | May 2014 → Dec 2015 | rheumatoid arthritis | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05535933 | Sep 2022 → Nov 2025 overdue | autoimmune hemolytic anemia, warm type | Hutchmed | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03951623 Comparator | Aug 2019 → Oct 2021 | autoimmune thrombocytopenia | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05029635 Comparator | Oct 2021 → May 2025 | autoimmune thrombocytopenia | Hutchmed | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sovleplenib | “Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.” PMID 37028433 ↗ Apr 20232“The purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).” NCT05029635 ↗ “Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with anti-tumor activity in preclinical models of B-cell malignancy.” PMID 38235512 ↗ Jul 2024 |
| Known as | HMPL-523 | “Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.” PMID 37028433 ↗ Apr 2023 |
| Known as | HMPL-523 Acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095034 ↗ |
| Known as | SOVLEPLENIB ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095034 ↗ |
| Action | Inhibit | “Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor” PMID 38235512 ↗ Jul 2024 |
| Modality | Small molecule | “selective small-molecule SYK inhibitor” NCT05720767 ↗ |
| Route | Oral | “Oral administration” NCT02105129 ↗ |
| Target | SYK | “Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor” PMID 38235512 ↗ Jul 2024 |